I am delighted to welcome you to a Takeda-organised satellite symposium at ECCO 2017: “Changing the Game in Ulcerative Colitis: Impact of Gut-Selective Therapy.”
Ulcerative colitis (UC) is a chronically progressive disease. However, its progressive nature is often overlooked, which can result in undertreatment. There is a need for resetting therapeutic expectations in patients with UC. First, early intervention is critical, especially in patients at high risk for colectomy. Second, complete recovery of colonic mucosal inflammation is important for ultimately slowing progression. Current guidelines recommend the therapeutic goals of clinical remission and endoscopic healing for the treatment of patients with UC. Healing of mucosa at the deeper histologic level has also been proposed as an adjunct goal, but consensus on its clinical utility is currently lacking.
Conventional and anti-tumor necrosis factor (TNF) agents are effective for the treatment of UC, but substantial unmet needs remain. Brian G. Feagan, MD, will discuss how some patients may not achieve adequate induction efficacy with conventional and anti-TNF agents, and some may not maintain optimal long-term remission and mucosal healing. There are also safety concerns with long-term use of anti-TNF agents and immunomodulators, particularly when the 2 agents are combined. Treatment of early disease with an efficacious and well-tolerated therapy is needed for achieving complete healing of UC for the long term.
Vedolizumab is a gut-selective α4β7 integrin antagonist that was recently recommended by the ECCO UC guidelines as a 1st-line biologic therapy for moderate–severe UC. Stefan Schreiber, MD, PhD, will provide an update on the latest clinical and real-world data that show vedolizumab was more effective in biologic-naïve patients and early in the disease course in inducing clinical and endoscopic remission. The clinical and endoscopic remission achieved with vedolizumab could be maintained for the long term with continuous treatment. Complete healing of mucosa at the histologic level was observed with vedolizumab therapy in patients with endoscopic remission. The favorable safety profile of vedolizumab supports the early and long-term use of this gut-selective agent for the treatment of moderate–severe UC.
We are confident this symposium will provide useful information that you can incorporate into your own practice for the successful management of patients with UC. On behalf of my fellow colleagues, thank you for joining us this morning. We also encourage you to attend today’s second Takeda-organised symposium— “Targeting Disease Progression in Crohn’s Disease: Fighting an Unrelenting Enemy”—which will be held at 12:40–13:20 in Plenary Hall, CCIB.
|07:15-07:20||Welcome & Introduction||CHAIR
Jean-Frédéric Colombel, MD
|07:20-07:30||Resetting Expectations for Therapy in Ulcerative Colitis||Jean-Frédéric Colombel, MD|
|07:30-07:45||Remission in Ulcerative Colitis: Has It Been Achieved and For How Long?||Brian G. Feagan, MD|
|07:45-08:05||Meeting Expecations for Therapy: Do Gut-Selective Biologics Deliver?||Stefan Schreiber, MD, PhD|
|08:05-08:15||Panel Discussions/Q&A||Jean-Frédéric Colombel, MD|
|Breakfast will be available|
Jean-Frédéric Colombel, MD, was Professor of Medicine and Head of the Dept of Gastroenterology at Centre Hospitalier Régional Universitaire de Lille in France, President of GETAID (Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives), President of ECCO, and Chair of the International Organization for the Study of Inflammatory Bowel Diseases. Dr Colombel moved to the Icahn School of Medicine at Mount Sinai in 2013 to become Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and the Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center. He is the author or co-author of more than 720 peer-reviewed articles and book chapters. Dr Colombel is Associate Editor of Gastroenterology. His research interests cover all fields of inflammatory bowel disease (IBD).
Brian G. Feagan, MD, completed his medical degree at the University of Western Ontario. His postdoctoral training included residency in the university’s Dept of Medicine and a fellowship in gastroenterology.
A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr Feagan holds membership in the Canadian Association of Gastroenterology, American Gastroenterological Association, American College of Gastroenterology, College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada, and ECCO. He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. Dr Feagan has authored over 200 articles and book chapters, and has given over 900 invited presentations at national and international scientific meetings.
In 1997, Dr Feagan became Director of Robarts Clinical Trials, Inc at the Robarts Research Institute of the University of Western Ontario. His research efforts focus on the design and implementation of randomized controlled trials of therapy for IBD. Dr Feagan has been the principal investigator on numerous large-scale randomized clinical trials.
Stefan Schreiber, MD, PhD, is Professor of Medicine and Director of the Institute of Clinical Molecular Biology at Christian-Albrechts-University, and Director of the Clinic of Internal Medicine at the University Hospital Schleswig-Holstein. Prof Schreiber is also a speaker for the “Inflammation at Interfaces” Cluster of Excellence, an initiative supported by the German Research Foundation. He completed a postdoctoral research fellowship in the Depts of Gastroenterology at Washington University in St. Louis, Missouri, USA, and the University of Pennsylvania in Philadelphia, USA, and went on to become a junior faculty member in the Dept of Gastroenterology at Charité University Hospital in Berlin, Germany. In 1996, Prof Schreiber was appointed Associate Professor at Christian-Albrechts-University. Since 2004, he has been Full Professor and Director of both the Dept of Internal Medicine I and the Institute for Clinical Molecular Biology.
Prof Schreiber’s main research focus has been on molecular genetics and the pathophysiology of chronic intestinal inflammation, development of new IBD therapies, and mechanisms involved in aging. He is a member of many professional societies including the American Gastroenterological Association, European Society for Clinical Investigation, Scientific Committee of the German Crohn's and Colitis Foundation, German Society of Internal Medicine, and German Society of Gastroenterology, Digestive, and Metabolic Diseases.
Prof Schreiber has been an invited lecturer and chairman at many national and international meetings. He is co-editor of several prestigious international journals focusing on IBD and genetics, and has authored more than 800 original publications in leading scientific journals.